Prognostic values of lipid panel data for macrovascular complication development in type 2 diabetic patients with comorbid thyroid dysfunction
This study aimed to evaluate prognostic values of the serum lipid panel data for development of macrovascular complications (MVC) in patients with type 2 diabetes mellitus (T2DM) alone and those with comorbid hypothyroidism (HT), diff use non-toxic goiter (DNTG), or a combination of these disorde...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sestre Milosrdnice University hospital, Institute of Clinical Medical Research
2024-01-01
|
| Series: | Acta Clinica Croatica |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/465469 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | This study aimed to evaluate prognostic values of the serum lipid panel data
for development of macrovascular complications (MVC) in patients with type 2 diabetes mellitus
(T2DM) alone and those with comorbid hypothyroidism (HT), diff use non-toxic goiter (DNTG), or
a combination of these disorders. Th e study included 596 inpatients. Receiver operating characteristic
(ROC) analysis was used to identify prognostically signifi cant values of total cholesterol (TC),
triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol
(LDL-C), non-HDL-cholesterol (non-HDL-C) and remnant cholesterol (RC). Th e following cut-off
points that determine the relative risk of MVC development were established: TC >5.11 mmol/L,
TG ≥2.03 mmol/L, LDL-C ≥2.97 mmol/L and non-HDL-C ≥4.29 mmol/L in T2DM patients with
comorbid HT; TC ≥4.97 mmol/L, TG ≥2.54 mmol/L, LDL-C ≥3.21 mmol/L and non-HDL-C
≥4.20 mmol/L in T2DM patients with comorbid DNTG; and TC ≥4.89 mmol/L, TG ≥1.56 mmol/L,
LDL-C ≥2.93 mmol/L, non-HDL-C ≥4.04 mmol/L and RC ≥1.14 mmol/L in those with comorbid
HT and DNTG. Th us, serum levels of TC, TG, LDL-C, non-HDL-C and RC can be used for
stratification of T2DM patients with comorbid thyroid dysfunction into the category of increased risk
of MVC development. |
|---|---|
| ISSN: | 0353-9466 1333-9451 |